Compass Pathways’ (CMPS) Buy Rating Reiterated at BTIG Research

BTIG Research reaffirmed their buy rating on shares of Compass Pathways (NASDAQ:CMPS) in a report issued on Monday morning,Benzinga reports. BTIG Research currently has a $14.00 target price on the stock.

Other equities research analysts also recently issued research reports about the company. Royal Bank Of Canada increased their price objective on Compass Pathways from $21.00 to $22.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 18th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Compass Pathways in a research report on Wednesday, January 21st. Compass Point set a $15.00 price objective on Compass Pathways in a research report on Thursday, February 12th. HC Wainwright increased their price objective on Compass Pathways from $40.00 to $70.00 and gave the stock a “buy” rating in a research report on Monday, March 2nd. Finally, Lifesci Capital upgraded Compass Pathways to a “strong-buy” rating in a research report on Thursday, February 12th. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $21.63.

Compass Pathways Price Performance

Compass Pathways stock opened at $8.75 on Monday. Compass Pathways has a one year low of $2.25 and a one year high of $10.21. The business has a fifty day moving average price of $6.54 and a 200-day moving average price of $6.42. The company has a debt-to-equity ratio of 0.55, a current ratio of 0.77 and a quick ratio of 0.77. The firm has a market capitalization of $1.13 billion, a P/E ratio of -2.83 and a beta of 2.01.

Compass Pathways (NASDAQ:CMPS) last posted its quarterly earnings results on Tuesday, March 24th. The company reported ($1.00) EPS for the quarter, missing analysts’ consensus estimates of ($0.41) by ($0.59). As a group, equities research analysts forecast that Compass Pathways will post -1.68 EPS for the current year.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the stock. Flax Pond Capital LLC purchased a new position in shares of Compass Pathways in the fourth quarter worth about $364,000. Caitong International Asset Management Co. Ltd bought a new stake in shares of Compass Pathways in the fourth quarter worth about $47,000. Seven Fleet Capital Management LP bought a new stake in shares of Compass Pathways in the fourth quarter worth about $276,000. Corient Private Wealth LLC grew its stake in shares of Compass Pathways by 3.2% in the fourth quarter. Corient Private Wealth LLC now owns 38,438 shares of the company’s stock worth $265,000 after purchasing an additional 1,200 shares during the last quarter. Finally, XTX Topco Ltd grew its stake in shares of Compass Pathways by 457.5% in the fourth quarter. XTX Topco Ltd now owns 56,786 shares of the company’s stock worth $392,000 after purchasing an additional 46,600 shares during the last quarter. Hedge funds and other institutional investors own 46.19% of the company’s stock.

Compass Pathways Company Profile

Compass Pathways (NASDAQ: CMPS) is a clinical-stage biotechnology company focused on the development and commercialization of psilocybin therapy for mental health disorders. Founded in 2016 and headquartered in London with additional offices in the United States, Compass Pathways is pioneering the use of synthetic psilocybin combined with psychotherapy to address treatment-resistant depression. The company’s flagship program is a Phase IIb clinical trial evaluating COMP360, its proprietary psilocybin formulation, which has received Breakthrough Therapy designation from the U.S.